ImmunogenIcity of thE PandemRIX A (H1N1) 2009 Influenza vaccine in hemodialysed and renal transplanted patients

Introduction Swine-origin pandemic human influenza A(H1N1)2009 rapidly spread around the world since its initial reporting on the 25th of April 2009. To counter the virus, different vaccines were developed. In Belgium, the Pandemrix vaccine of GSK was used. Part of the Belgian population was vaccinated, especially those belonging to risk groups (immunodepressed patients, healthcare providers, patients with chronic disease, pregnant women, ....). In general, vaccine immunogenicity is less effective in immunodepressed patients than in immunocompetent patients. In this study the immunogenicity of the Pandemrix vaccine was investigated by measuring neutralizing antibodies against A(H1N1)2009 in sera collected from immunocompetent and immunodepressed patients such as hemodialysed and renal transplanted patients.